Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

The relationship between low-density lipoprotein cholesterol levels and the incidence of cardiovascular disease in high-risk patients treated with pravastatin: main results of the APPROACH-J study.

Daida H, Teramoto T, Kitagawa Y, Matsushita Y, Sugihara M.

Int Heart J. 2014;55(1):39-47. Epub 2014 Jan 27. Erratum in: Int Heart J. 2014;55(2):184.

3.

Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.

Uchiyama S, Nakaya N, Mizuno K, Ohashi Y, Tajima N, Kushiro T, Teramoto T, Nakamura H; MEGA Study Group..

J Neurol Sci. 2009 Sep 15;284(1-2):72-6. doi: 10.1016/j.jns.2009.04.002. Epub 2009 May 6.

PMID:
19423132
4.

HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.

Tani S, Nagao K, Hirayama A.

Am J Cardiovasc Drugs. 2011 Dec 1;11(6):411-7. doi: 10.2165/11594620-000000000-00000.

PMID:
22149320
5.

The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.

Sakamoto K, Sakamoto T, Ogawa H; Kumamoto Joint Research on Hypercholesterolemia Investigators..

Clin Ther. 2006 Jul;28(7):1012-21.

PMID:
16990079
7.

Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.

Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T.

Int J Cardiol. 2005 Sep 30;104(2):213-23.

PMID:
16168816
8.

[Statins in primary prevention of coronary heart disease].

Paulweber B.

Wien Med Wochenschr. 1999;149(5-6):129-38. Review. German.

PMID:
10408004
9.
11.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group..

Clin Ther. 2004 Sep;26(9):1388-99. Erratum in: Clin Ther. 2005 Jan;27(1):142.

PMID:
15531001
12.

Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial.

Horiuchi H, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H; J-LIT Study Group..

J Am Geriatr Soc. 2004 Dec;52(12):1981-7.

PMID:
15571531
13.

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.

Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A; LIPID Study Investigators..

Eur Heart J. 2004 May;25(9):771-7.

PMID:
15120888
14.
15.

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).

Smith DG, McBurney CR.

Pharmacoeconomics. 2003;21 Suppl 1:13-23.

PMID:
12648031
16.

The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia.

Ishikawa T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, Uchiyama S, Nakamura H; MEGA Study Group..

Circ J. 2008 Oct;72(10):1576-82. Epub 2008 Aug 29.

17.

Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

Sasaki J, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Itakura H, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators..

J Atheroscler Thromb. 2012;19(2):194-204. Epub 2011 Dec 17.

19.

Adherence to preferable behavior for lipid control by high-risk dyslipidemic Japanese patients under pravastatin treatment: the APPROACH-J study.

Kitagawa Y, Teramoto T, Daida H; APPROACH-J Study group..

J Atheroscler Thromb. 2012;19(9):795-805. Epub 2012 Jun 6.

20.

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.

Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, Furberg CD, Braunwald E.

Circulation. 2002 Mar 26;105(12):1424-8.

Supplemental Content

Support Center